HOME > OUR WORLD > BUSINESS > FORMULATIONS BUSINESS

OVERVIEW

"THE US IS LUPIN’S LARGEST AND MOST IMPORTANT MARKET AND INTEGRAL TO THE COMPANY’S PERFORMANCE. HEADQUARTERED IN BALTIMORE, MARYLAND, THE COMPANY’S US SUBSIDIARY, LUPIN PHARMACEUTICALS, INC. (LPI), IS DEDICATED TO DELIVERING HIGH-QUALITY, BRANDED AND GENERIC MEDICINES TRUSTED BY HEALTHCARE PROFESSIONALS AND PATIENTS ACROSS THE US."

LPI enjoys strong brand equity in the US wholesale and retail channels as a preferred supplier of quality generics and is an emerging specialty major focusing on Paediatric specialists and Primary Care physicians. Strong commercial capabilities in the US market for both generic and branded products have made LPI a key contributor to the Company’s growth.

FY 2016 was a year of heightened activity and consolidation in the US as we navigated our way through a fast changing and volatile pharmaceutical marketplace while maintaining growth momentum and performance. Lupin clocked in US revenues of USD 887 million during FY 2016, contributing 43% of the Company’s global revenues. This business performance has made Lupin the 5th largest pharmaceutical player in the US (4.68% market share by prescriptions – IMS Health, National Prescription Audit, MAT March 2016).

USA

FORMULATIONS BUSINESS